Malignant HematologyThe Malignant Hematology team in the Division of Hematology/Oncology at The University of Texas Health Science Center at Houston (UTHealth) provides comprehensive, patient-centered care for patients diagnosed with cancers of the blood.
The Malignant Hematology team’s mission is to:
- Provide high-quality, personalized medical care to patients diagnosed with, suspected of having, or at high risk for leukemia, lymphoma, or multiple myeloma in a well-coordinated, multidisciplinary fashion so as to improve, enhance, and sustain quality of life
- Educate current and future health care providers and general practitioners on various aspects of blood cancers
- Contribute to advances in biomedical research in the areas of prevention, screening, and treatment of hematologic malignancies
- Promote good health in our community through collaborations with physicians and local leaders and patient advocacy groups
Our team of highly skilled physicians and allied healthcare professionals provides consultation and management in both the outpatient and inpatient setting at Memorial Hermann TMC.
We provide comprehensive care through collaboration with members of the Divisions of Surgery, Radiation Oncology, Pathology, and Radiology and includes multidisciplinary tumor board conferences and coordination of care through the Memorial Hermann Cancer Center for the treatment of Acute and Chronic Leukemias, Malignant Lymphomas, and Plasma Cell Disorders (Multiple Myeloma, MGUS and Amyloid-related Disorders).
These services include genetic counseling, infusion services, palliative care, and social work. Home care and follow ups visits are coordinated by a team of expert nurse navigators.
The program for the management and treatment of acute leukemia is unique at McGovern Medical School and the Memorial Hermann System. It provides easy access for patients with acute leukemia either by direct referral or hospital-to-hospital transference from other institutions.
A unique feature of this program is the designation of a permanent regular bed for the Leukemia Program in the chemotherapy unit. This allows the seamless transfer of cases to the leukemia floor and prompt initiation of therapy.
We are committed to be a resource to the patients with acute leukemia in the Memorial Hermann System and in the greater Houston area.
Our comprehensive array of programs allows us to be of service to patients with acute leukemia with specific clinical situations such as those with acute leukemia during pregnancy as well as patients with complex cardiovascular conditions.
Physicians needing to transfer a patient for urgent care may contact the Memorial Hermann System Transference Center at 713.704.2500.
Rios A, Hersh EM, Gutterman JU, Mavligit GM, Schimek H, McEntire J, Papermaster B. The use of leukocyte cell cultures supernatant for skin reaction testing in malignant melanoma. Cancer 1979;44:1615-7
Toki H, Hersh EM, Gutterman J, Haynie P, Glenn H, White RA, Rios A. Organ distribution and clearance studies of technetium-labeled corynebacterium in patients with leukemia. International Journal of Immunopharmacology 1981;3:141-5
Cortes J, Thomas D, Rios A, Koller C, O’Brien S, Jeha S, Faderl S,Kantarjian H. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002;94(5):1492-9
Tsimberidou AM, Medina J, Cortes J, Rios A, Glisson, B, Faderl S. Kantarjian H, Garcia-Manero G. Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. Leukemia Research 2004;28(6):657-60
Rios A. HIV-related hematological malignancies: a concise review.
Clinical Lymphoma, Myeloma, Leukemia 2014:SOHO suppl;S96
Quesada AE, Rios A, Brown RE, Nguyen ND. Expression of constitutively activated NF-kB/mTOR pathway and response to CHOP with bortezomib in a patient with angio-immunoblastic peripheral cell lymphoma. Clinical Lymphoma, Myeloma Leukemia 2014;SOHO suppl:S87
Quesada AE, Binara A , Jabcuga CE , Zhang R, Covinsky M, Rios A, et al. Expression of Sirt1 and FoxP3 in classical Hodgkin lymphoma and tumor infiltrating lymphocytes: Implications for immune dysregulation, prognosis and potential therapeutic targeting. International Journal of Clinical & Experimental Pathology 2015;8(10):13241-8
Rios A, Gonzalez A, Dinh B, Cervoni-Curet F, Yang W, Rekoff J, Chen L, Wahed A, Nguyen ND. Rituximab-COP-revlimid treatment of high-grade diffuse large B-cell lymphoma (HG-DLBCL) of the elderly with lenalidomide, rituximab, cyclophosphamide, and prednisone (abstract). Presented at the Eighth Annual SOHO Conference, 2020
Cervoni-Curet F, Yohannan B, Miao H, Rios A. Secondary hemophagocytic lymphohistiocytosis (HLH): five years’ experience at the UTHealth McGovern Medical School at Houston, Texas (abstract). Presented at the ASCO Annual Meeting, 2021.
George B, Kantarjian H, Baran N, Krocker JD, Rios A. TP53 in acute myeloid leukemia: molecular aspects and patterns of mutation. International Journal of Molecular Sciences 2021;22:10782
Rios A, Yohannan B, Cervoni-Curet F. Induction mortality (IM) of acute myeloid leukemia (AML) patients treated with purine analogues-cytarabine-anthracycline at a general hospital (abstract). Presented at the ASCO Annual Meeting, June 2022
Rios A, Yohannan B, Cervoni-Curet F. Clinical outcomes of patients with FLT3-mutated acute myeloid leukemia (AML): a single center retrospective review (abstract). Presented at the ASCO Annual Meeting, June 2022
Thomas N , Yohannan B, Sridhar A, Rios A. Myeloproliferative neoplasm (MPN) post-renal transplant (RT)—a single center review (abstract). Presented at the Tenth Annual SOHO Conference, 2022
Yohannan B, Cervoni-Curet F, Rios A. Early deaths in patients with newly diagnosed acute promyelocytic leukemia: a single-center retrospective study from a general hospital (abstract). Presented at the Tenth Annual SOHO Conference, 2022
Yohannan B, Cervoni-Curet F, Rios A. A single institution experience on clinical outcomes of TP-53 mutant acute myeloid leukemia (AML) (abstract). Presented at the Tenth Annual SOHO Conference, 2022
Rios A, Hagemeister FB. The acquired immunodeficiency syndrome-related cancers (chapter 52). In: MD Anderson Cancer Manual of Oncology, 4th ed. McGraw Hill Education, 2022:1223-51
George B, Gonzalez A, Rios A. Inside the biology of acute leukemias of ambiguous lineage: diagnostic work-up, genomic, and clinical characterization. Journal of Cancer Science and Clinical Therapeutics 2022 (in press)